NAT8 is a putative N-acetyltransferase involved in metabolic processes. The Anti-NAT8 Antibody (A38709) is a commercially available reagent with the following characteristics :
Detects NAT8 in mouse kidney and liver tissues (40 µg lysate, 1:237.5 dilution) .
Used in IHC for human cervical cancer tissue analysis (1:50 dilution) .
ANXA8 is a calcium-dependent phospholipid-binding protein implicated in cancer progression and endosomal trafficking. The Human Annexin A8/ANXA8 Antibody (AF8105) is a well-characterized tool :
Cancer Prognosis: High ANXA8 expression correlates with poor outcomes in ovarian cancer .
Cellular Localization: Expressed in endothelial cells of human placenta and upregulated in mammary hyperplasia and pancreatic adenocarcinoma .
Western Blot: For NAT8, use 8% SDS-PAGE with mouse kidney/liver lysates . For ANXA8, reducing conditions are recommended .
IHC Protocols: NAT8 requires paraffin-embedding and antigen retrieval , while ANXA8 staining uses heat-induced epitope retrieval (Antigen Retrieval Reagent-Basic) .